Serum biomarkers for the early diagnosis of minimal hepatic encephalopathy
DOI:10.3969/j.issn.1001-5256.2020.12.037
- VernacularTitle:轻微肝性脑病早期诊断的血清生物学标志物
- Author:
Qinfu ZHANG
1
;
Huanqin HAN
;
Weiqiang ZHENG
Author Information
1. Infectious Diseases Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, China
- Publication Type:Research Article
- Keywords:
hepatic encephalopathy;
biomarkers;
diagnosis
- From:
Journal of Clinical Hepatology
2020;36(12):2819-2821
- CountryChina
- Language:Chinese
-
Abstract:
Minimal hepatic encephalopathy (MHE) refers to a state of neuropsychological or neurophysiological abnormality and normal cognitive function in patients with liver cirrhosis, which is commonly seen in patients with liver cirrhosis. Early diagnosis and treatment of MHE can improve the quality of life of patients and reduce accidental deaths. At present, Psychometric Hepatic Encephalopathy Score is mainly used for the diagnosis of MHE, but its operation is complicated and time-consuming and is affected by age and educational level, with unsatisfactory reliability in clinical diagnosis. Serum biomarkers are objective reference indicators with simple and convenient measurement and can easily be promoted in clinical practice. Potential serum biomarkers such as S100β, 3-nitrotyrosine, and arterial blood ammonia have their own advantages and disadvantages in specificity, sensitivity, and diagnostic value. This article reviews the above-mentioned serum biomarkers.
